VOLUME 35 1990

SUBJECT INDEX

ACTH, 739
ACTH analog, 99
Acetylcholine, 143, 523
Acquisition, 553
Activity, 511
Activity monitor (wheel-shaped), 1003
Adenosine, 85, 791
Adrenalectomy, 171, 739, 753
Adrenoceptors, 41
Adrenocorticotropin, 99
Adrenoreceptors, 21
Afterdischarges, 815
Aggression, 699
Aggressive behavior, 357
Aging, 589, 747
Alcohol, 357, 693
Alcohol-barbiturate combination, 443
Alcohol drinking, 465
Alcohol sensitivity, 437, 721
Allantoxanamide, 791
Alprazolam, 651
Alprazolam brain levels, 651
Alprazolam dependence, 643
Alprazolam plasma levels, 651
Alzet minipumps, 219
Amantadine, 29, 291
Amino acid analog, 911
Amino acids, 127, 133, 195
Amnesia, 747
Amphetamine, 55, 89, 121, 219, 301, 461, 517, 595, 871, 989
d-Amphetamine, 457, 631, 759
(+)-Amphetamine, 971
Amygdala, 815
Analgesia, 137, 157, 225, 567, 731
Analgesic drugs, 567
Androgens, 307
Anhedonia, 273
Anorectic drugs, 301
Anorexia, 51, 61, 457, 461
Anorexia nervosa, 885
Anticonvulsant drugs, 537
Anticonvulsants, 815
Antineoplastic, 767
Antipanic, 451
Antipsychotic effect, 937
Anxiety, 451, 775, 923
Anxiety model, 713
Anxiogenesis, 263
Anxiolysis, 85, 263
Anxiolytic effect, 503
Anxiolytic profile, 607
Anxiolytics, 121
Apomorphine, 117, 201, 391, 511, 583, 659, 753, 937, 989
Apomorphine-induced climbing, 93
Appetite, 61, 865
Area postrema, 543
Ascorbate, 55
Ascorbic acid, 871
D-Aspartic acid, 47
Ataxia, 815
Atria, 99
Attenuation of abstinence syndrome, 47
Autoimmunity, 747
Autonomic nervous system, 21
Autoreceptor, 201
Aversion learning, 543
Avoidance behavior, 685
Avoidance learning, 747

BC-105, 61
BMY 21502, 553
BW A78U, 85
Barbiturate, 317, 889
Behavior, 117, 631, 713, 847, 911
Behavioral, 7
Behavioral history, 405
Behavioral measures of anxiety, 121
Behavioral tolerance, 273, 561
Behavioral toxicology, 583
Benzodiazepine inverse agonist, 889
Benzodiazepine receptor antagonist, 747
Benzodiazepine receptors, 503
Benzodiazepines, 121, 281, 373, 379, 841
Beta-adrenoceptors, 335
Beta carboline carboxylic acid ethyl ester (BCCE), 713
Binding sites, 99
Biogenic amines, 989
Blood acetaldehyde, 437
Body temperature, 511
Body weight, 219, 301
Brain, 465, 511, 995
Brain cortex, 255
Brain development, 943
Brain evoked potential, 341
Brain injury, 497
Bright light, 523
Buspirone, 117, 781

C57BL/6J, 311
C57BL/6NNia mice, 747
CCK-8, 493
CPP, 785
mCPP, 181
CY 208-243, 105
Caerulein, 143, 855
Caffeine, 477, 631, 791
Calcium channel antagonists, 557
Calcium channel inhibitors, 601
Calcium channels, 833
Caloric intake, 301
Carbamazepine, 897
Carbohydrates, 665, 923
Carbon monoxide, 341
Cardiovascular changes, 437
Catalepsy, 753
Catecholamines, 165
Catecholestrogens, 307
Caudate, 871
Cerebellum, 693
Cerebral ventricle, 465
Chickens, 567
Chlordiazepoxide, 363, 373, 451, 897
Chlordiazepoxide metabolism, 363
p-Chloroamphetamine, 995
N-[4-(2-Chloromethylamino)]-2-pyrrolidone (BM 123), 511
p-Chlorophenylalanine, 847
Chlorophenylpiperazine, 181
Chlorpromazine, 29, 897
Choice, 413
Choice test, 15
Cholecystokinin, 51
Cholecystokinin-octapeptide, 143, 493
Choline, 143
Choline acetyltransferase (ChAT), 589
Cholinergic, 523
Cholinergic receptors, 171
Cholinergic system, 903
Cholinesterase, 561
Chronic, 291
Chronic administration, 477, 933
Chronic benzodiazepine, 419
Chronic diet treatment, 363
Chronic drug treatment, 489
Chronic ethanol consumption, 75
Chronic intrathecal injection, 807
Chronic treatment, 481
Chronic variable stress, 335
Cingulate cortex, 871
Circadian rhythms, 35, 923
Circling behavior, 877
Classical conditioning, 583
Clonazepam, 815, 933
Clonidine, 35
Cocaine, 121, 187, 237, 245, 269, 595, 17, 631, 743, 949
Cocaine analogs, 949
[^{3}H] Cocaine binding, 949
Cocaine preference, 187
Cocaine self-administration, 245
Codeine, 413, 567
Cognition, 955
Cognitive decline, 747
Concurrent schedules, 443
Conditioned drug effects, 367
Conditioned place aversion, 89
Conditioned place preference, 89, 485
Conditioned taste aversion, 583, 803
Conditioned taste avoidance, 583
Conditioning, 373
Conflict behavior, 451
Conflict test, 413
Consolidation, 127, 133
Convulsions, 85
Convulsive crises, 713
Cortex, 589
Cortical choline acetyltransferase, 151
Corticosterone, 739
Corticostriatal pathway, 55
Cotreatment, 291
Counter-irritation, 731
Cricket, 127, 133
Cross tolerance, 637, 807
Cumulative dosing, 537
Cytisine, 735

D-1 receptors, 285
D1 and D2 DA receptor interactions, 877
D-1 and D-2 receptors, 105
D-2 receptors, 285
D_2 receptors, 117
DA receptors, 937

DBA/2J, 311
DFP, 561
DMBA, 767
l-DOPA, 465
DOPAC, 195
DRL, 595
Defense, 775
Defensive burying, 451
Delayed nonmatching to position procedure, 903
Delta, kappa and mu opioid receptors, 69
2-Deoxyglucose, 865
Dependence, 137
Dependence, oxazepam, 347
Desipramine, 451
Development, 693
Dextromethorphan, 829
Diabetes, 473, 577
Diazepam, 121, 263, 405, 419, 775, 933
Diazepam withdrawal, 419
Diet, 225, 911
Diet selection, 665
α-Difluoromethylornithine, 255
Dihydropyridine binding sites, 833
[^{125}I]-2-(2,5-Dimethoxy-4-iodophenyl)amino-ethane, 211
Discrete brain, 143
Discrimination, 517
Discriminative stimulus, 351
Domestic fowl, 567
Dopa-decarboxylase inhibition, 465
Dopamine, 105, 111, 117, 195, 201, 285, 291, 327, 465, 497, 577, 643, 659, 685, 735, 743, 937, 995
Dopamine and 5-HT receptor antagonist, 607
Dopamine antagonist, 351
Dopamine receptors, 93, 511
Dorsal immobility response, 307
Dose response, 861
Dosing schedule, 273
Drinking, 69
Drug abuse, 517, 743
Drug-admixed food, 413
Drug cumulation, 273
Drug discrimination, 117, 405, 527, 537, 781, 797, 949, 971
Drug interactions, 443
Drug reinforcement, 443
Drug reward, 485
Drug seeking behavior, 413
Drug self-administration, 311
Duration of action, 861
Dynorphin, 429, 643

E.A.A. antagonists, 999
EEG, 933
Elation, 923
Elevated plus-maze, 721
Endogenous opioids, 69
β-Endorphin, 807
Energy restriction, 677
Epilepsy, 815
Epileptiform activity, 999
Estradiol, 307
Estrogen, 767
Ethanol, 259, 363, 465, 485, 775, 803
Ethanol/alcohol, 443
Ethanol-chlordiazepoxide cross-dependence, 379
Ethanol intake, 379, 493
Ethanol metabolism, 363
Ethanol self-administration, 259
Ethanol sensitivity, 469
N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), 877
Experience-induced plasticity, 255
Exploration, 201, 317, 557
Exploratory activity, 121, 503, 855

FG7142, 889
Facial flushing, 437
Fasting, 391
Fat, 665, 671
Feed efficiency, 301
Feeding, 225
Fenfluramine, 527, 971
Fetal alcohol syndrome, 693
Fetus, 943
Fixed-ratio schedules, 443
Flesinoxan, 781
Flumazenil, 347, 503, 747, 889
Flumazenil plasma levels, 651
Flumazenil precipitated abstinence in dogs, 651
Fluoxetine, 51, 237, 259
Fluprazine hydrochloride, 699
Food choice, 911
Food deprivation, 865
Food intake, 61, 461, 493, 865, 911
Food-reinforced behavior, 481
Forced swimming test, 557
Free fatty acids, 677
Free rhesus monkeys, 713
Freezing behavior, 685

GR38032F, 955
Genetic, 15
Genetic selection for differences in ethanol preference, 385
Glucose, 677
Glutamate, 815
Glycolipid, 75
Glycosyltransferase, 75
Growth, 911
Guinea pig ileum-myenteric plexus, 705
Gulls, 7

5-HT, 61, 157
5-HT$_1$ sites, 335
5-HT$_{1A}$, 781
5-HT$_{1A}$ agonists, 251
5-HT$_{1A}$ receptors, 251
5-HT1B stimulation, 841
5-HT$_2$ receptor, 211, 251
5HT$_3$ receptor, 955
HVA, 195
Habituation, 151
Hallucinogens, 211
Haloperidol, 111, 273, 291, 391, 457, 481, 753, 855, 897
Halothane, 889
Head-shake response, 151
Hedonics, 671
Heroin, 351
Herpes simplex virus-type 1, 617
γ-Hexachlorocyclohexane, 1003
Hibernation, 705
Hibernation-induction trigger (HIT), 705
High-carbohydrate diet, 301
High-fat diet, 301
Hippocampal slices, 999
Hippocampal sympathetic ingrowth, 21
Hippocampus, 589, 785, 847, 871
Humans, 157, 397
Humoral immunity, 617
Hunger, 923
3-Hydroxybenzylhydrazine dihydrochloride, 465
5-Hydroxytryptamine, 943
Hyperalgesia, 567
Hyperphagia, 373, 865
Hypersensitivity, 291
Hypoalgesia, 567
Hypophysectomy, 739

([^{125}I]-2C-I), 211
Imipramine, 335, 451
Inbred mice, 121
Indomethacin, 601
Ingestion, 15
Ingestive behaviors, 583
Inhibition, 231
Inhibitors, 561
Insulin, 865
Intense grooming, 105
Intensification of abstinence syndrome, 47
Intensity, 671
Intracerebroventricular, 69
Intramuscular dosing, 797
Intrathecal, 1
Intravenous, 237
In vivo, 55
Irreversible muscarinic agonist, 511
Isolated mice, 841

Kainic acid, 1
Ketamine, 829
Ketanserin, 181
Kindling, 815
Kinetics of response, 797
Kinins, 437
Kynurenic acid, 815

LH releasing hormone, 577
LY 171555, 877
Large neutral amino acids, 911
Lead, 7
Learning, 21, 127, 133, 631
Learning and memory, 981
Leucine, 911
Level of arousal, 269
Light/dark choice procedure, 85
Lindane, 1003
13-Lined ground squirrel (*Citellus tridecemlineatus*), 705
Lithium, 291, 897
Locomotion, 85, 735
Locomotor activity, 35, 231, 481, 617, 791, 897
Long-sleep and short-sleep mice, 469
Long-term potentiation, 533, 785
Long-term treatment, 855

MDA, 971
MDMA, 971
MK-212, 181
MK-329 (L-364,718), 51
MK-801, 533, 785, 815
MR2266, 69
Maharishi-4, 767
Male rat, 327
Male rat sexual behavior, 263
Male sex behavior, 659
Mammary tumors, 767
Mania, 897
Massed extinction, 41

Meal size, 923
Medial septal lesions, 21
Memory, 21, 127, 133, 553, 747, 903
Meprobamate, 405
3-Mercaptopropionic acid, 721
Mesencephalon, 989
Mesolimbic-mesocortical DA system, 937
Metabolism, 291
Methamphetamine, 391, 637, 897
4-Methylaminorex, 517
N-Methyl-D-aspartate, 785
Methyl β-carboline-3-carboxylate, 281
16-Methyl cyprenorphine, 69
Methylenedioxyamphetamine, 637
Methylenedioxymethamphetamine, 637
Methylphenidate, 121
α-Methyl-dl-p-tyrosine, 201
Methysergide, 181
Metoclopramide, 285, 685
Mianserin, 181
Mice, 85, 231, 285, 357
Microanalysis of behavior, 1003
Microcomputer, 1003
Microdialysis, 201
Milk-drinking, 637
Miniature endplate potentials, 321
Monkeys, 553, 759, 949
Monoacetylmorphine, 351
Monoamine, 391
Monoamine-related substrates, 231
Mood states, 861
Morphine, 15, 137, 157, 225, 231, 311, 351, 367, 413, 567, 595, 643, 665, 807
Morphine dependence, 47
Motivation, 219
Motor activity, 317
Motor behavior, 285
Motor impairments, 273
Motor performance, 419
Mouse, 143, 281, 317, 391
Mouse strains, 29
Multidimensional scaling, 397
Multiple-trial learning, 281
Muscarinic receptors, 511, 589

NMDA, 815
NMDA receptor, 533
NSD-1015, 465
NZB/BlNJ mice, 747
Naloxone, 385, 567, 665, 705
Naltrexone, 1
Narcotic antagonists, 567
Narcotic drugs, 567
Negative allesthesia, 885
Neocortex, 847
Neonate, 571
Neostriatum, 55, 989
Neurofilament, 693
Neuroleptic agent, 607
Neuroleptic drugs, 685
Neuroleptics, 111
Neuromuscular transmission, 321
Neuronal uptake, 99
Neurotoxicity, 995
Neurotransmitter, 195
Nicotine, 171, 341, 489, 523, 671, 735
Nociception, 225, 473
Nonbenzodiazepine tranquillizing drugs, 841
Nonreward, 41
Nonsmokers, 671
Nootropic, 553
Noradrenaline, 41, 327
Nor-binaltorphimine, 69
d-Norephedrine, 865
d,l-Norephedrine, 865
l-Norephedrine, 457, 865
Norepinephrine, 497, 577
Norepinephrine turnover, 677
Norfenfluramine, 527
Norleucine, 911
Nucleus accumbens, 871
Nucleus basalis magnocellularis lesions, 151

8-OH-DPAT, 781
ORG 5222, 607
Odor, 775
Odor detection, 699
Olfaction, 699
Olfactory associations, 617
Olfactory threshold, 699
Ondansetron, 955
Open-field activity, 165
Operant behavior, 181
Operant responding, 111
Operant test battery, 759
Opiate, 219, 397, 567
Opiate-induced feeding, 665
Opiate system, 885
Opioid, 1, 385, 397, 567, 705
Opioid antagonists, 69
Opioid peptides, 767
Opioid physical dependence, 311
Opioid receptors, 1
Oral administration, 861
Oral route, 245, 443
Organochlorine insecticides, 1003
Organophosphates, 321
Oxazepam, 347
Oxytocin, 601

PCP, 93
PCP receptors, 1
PK 11195, 933
PLG, 47
Pain, 225, 341, 567, 731
Palatability, 583
Panic disorder, 451
Pantethine, 165
Papaverine, 29
Parachlorophenylalanine, 731
Pargyline, 451
Passive avoidance, 727
Penicillin, 999
Penile erection, 601, 659
Pentobarbital, 405, 443, 889
Performance, 269
Pergolide, 201
Perifornical hypothalamus, 461
Pertussis toxin, 137
Pharmacokinetics, 797
Phencyclidine, 93, 533, 797
Phentolamine, 21
Phenylpropanolamine, 457, 461, 865
Phenytoin, 537
Phospholipidic effectors, 75
Physical dependence, 15
Pigeons, 537, 631, 797, 971
Pilocarpine, 871
Pirenzepine, 589
Pituitary adrenal, 739
Pizotifen, 61
Plasma membrane, 75
Polar bear (*Ursus maritimus*), 705
Polydrug abuse, 443
Postnatal, 7
Postoperative pain, 157
Precipitated abstinence, 829
Predator, 775
Preference, 15, 413
Prefrontal cortex, 743
Prenatal exposure, 617
Primates, 659
Progesterone receptors, 767
Prolactin, 767
Propranolol, 21, 41
Prostaglandins, 601
Protein, 665
Pseudocatalepsy, 753
Psychopharmacology, 397
Purkinje cell, 693
Putrescine, 255

[^{3}H] QNB binding, 511
Quinuclidinyl benzilate (QNB), 589
Quipazine, 181
Quipazine-induced head shake response, 251

RO15-1788, 263, 379, 503, 651
RO15-4513, 803, 889
Ro 5-4864, 933
Radial arm maze, 533, 785
Radial maze, 429
Radioligand binding, 855
Rat, 15, 35, 41, 61, 89, 93, 151, 165, 195, 219, 237, 255, 259, 269, 273, 405, 413, 429, 481, 511, 527, 543, 557, 595, 601 637, 699, 739, 781, 933, 995, 999, 1003
Receptor, 291
ω_3 Receptor, 933
Receptor binding, 211
Recovery of function, 497
Reflex development, 617
Reinforcement, 89, 259, 595
Reinforcement density hypothesis, 273
Reinforcing effect, 413
Relative reinforcing effects, 443
Repeated acquisition, 631
Repeated administrations, 111
Repeated measures, 753
Repeated treatment, 557
Reserpine, 201
Responses to mirrors, 121
Restrained rhesus monkeys, 713
Retention, 151
Rhesus monkeys, 117, 245, 443, 659
Righting reflex, 889
Risk assessment, 775

SCH 23390, 111, 285, 877
SKF 38393, 877
Saccharin/glucose, 69
Saccharin intake, 219
Satiety peptide, 493
Schedule-induced wheelrunning, 739
Schedule induction, 187
Scopolamine, 291, 847
Scopolamine methyl nitrate, 543
Scratching, 1
Sedation, 85
Seizure susceptibility, 721
Seizures, 815
Selected rat lines, 721
Self-administration, 187, 237
Self-stimulation, 743
Senescence-accelerated mice, 727
Sensitivity, 671

Sensitization, 273
Sensorimotor cortex, 497
Septum, 989
Serotonin, 51, 61, 237, 465, 571, 995
Serotonin agonists, 181
Serotonin depletion, 731
Serum cocaine, 187
Serum drug levels, 617
Sex behavior, 577
Sex differences, 903
Sexual arousal, 367
Sexual behavior, 327, 571, 643
Sexual behavior in male rats, 367
Sexual differentiation, 357
Sigma receptors, 1
Signal detection, 699
Skills performance, 861
Smokers, 671
Smoking, 341
Social facilitation, 923
Social isolation, 469
Sodium appetite, 823
Soman, 561
Somatostatin, 165
Spatial memory, 429, 785
Specific appetite, 489
Spermidine, 255
Spermine, 255
Spinal cord, 473
Spontaneous behavior, 981, 1003
Squirrel monkeys, 181
Staircase test, 85
Stereotypic behavior, 291
Stereotypy, 511
Stimulants, 517
Stimulation, 231
Strain differences, 171
Stress, 41, 943
Stress-induced ACTH corticosterone and prolactin responses, 963
Striatum, 231, 307, 511, 589
Strychnine, 833
Subchronic administration, 477
Subjective effects, 397
Subjective response, 341
Substance P, 473
Sucrose, 225, 489
Sufentanil, 219
Sulpiride, 285
Suppression of abstinence syndrome, 829
Sweet, 671

TFMPP, 181
TRH, 727
Tachykinins, 823
Tail-flick, 225
Taste aversion, 219
Taste reactivity test, 583
Telemetry, 523
Tertiary and quaternary naltrexone, 963
Testicular enzymes, 29
Testosterone, 357, 577
Δ^9-Tetrahydrocannabinol, 861
Thermal nociception, 567
Thermoregulation, 523
Thioridazine, 291, 937
Thirst, 823, 923
Time-course, 527
Tolerance, 317, 321, 373, 637, 807
Trazodone, 181
Triazolam, 405
Trifluoromethylphenylpiperazine, 181
Tryptophan, 157, 943
Turning, 989
Tyrosine, 195

Uric acid, 791, 871

Vagotomy, 143
Vasopressin, 981
Ventral tegmental area, 643, 735
Ventromedial thalamic nucleus, 55
Vertical and horizontal locomotion, 391
Vibrissae, 989
Vigilance, 269
Volatile anesthesia, 889
Voltammetry, 55, 871
Voluntary ethanol consumption, 385

Water intake, 111
Water maze, 429
Weight pulling method, 413
Wheelrunning, 477
Withdrawal, 219, 317
Withdrawal signs, 379
Working memory, 533

YM-14673, 727
Yawning, 201, 601

Zk 39106, 263
Zopiclone, 405

AUTHOR INDEX

Abbott, F. V., 157
Abe, E., 391
Abla, K. A., 121
Abou-Issa, H., 767
Abraham, W. C., 785
Ågmo, A., 327
Agüero, A., 543
Allikmets, L., 855
Alling, C., 165
Alliot, J., 981
Amato, G., 937
Amdur, R. L., 291
Amstrup, S. C., 705
Andre, E., 713
Anton, G., 713
Apfelbaum, M., 885
Aragort, W., 133
Argiolas, A., 601
Aricioğlu, F., 47, 829
Arnedo, M., 543
Asencio, M., 237
Ashe, W. K., 617
Ator, N. A., 405
Aubin, H. J., 713
Axt, K. J., 995

Baker, G. B., 847
Baklien, A., 127
Banks, A. N., 93
Barber, D. J., 51
Barnes, J. M., 955
Barrera, C. M., 791
Basse-Tomusk, A., 55
Bassett, J. R., 99
Basso, A. M., 335
Beardslee, S. L., 451
Belknap, J. K., 311
Bernabei, A. A., 589
Biggio, G., 877
Bird, K. D., 861
Blackburn, J. R., 685
Blair-West, J. R., 823
Blanchard, D. C., 775
Blanchard, R. J., 775
Blau, S., 127
Bolger, G. T., 833
Bossut, D. F., 1
Bourguignon, J.-J., 85
Boyeson, M. G., 497
Bozarth, M. A., 485
Brodish, A., 963
Brosseau, L., 583
Bruce, D. S., 705
Burger, J., 7
Burton, L. E., 617
Butelman, E. R., 533

Calcagnetti, D. J., 69
Calcagnetti, R. L., 69
Calvino, B., 731
Calzà, L., 937
Cancela, L., 335
Canfield, D. R., 949
Cao, W., 121
Cappell, H., 373
Carroll, M. E., 237
Carvey, P. M., 291
Casanova, M. F., 693
Casas, M., 481, 753
Chan, A. W. K., 363, 379
Chance, W. T., 195
Chandler, C. J., 285
Chapouthier, G., 281
Chesher, G. B., 861
Clark, R., 537
Clark, W. C., 397
Cockroft, R., 461
Coen, K. M., 351
Coghill, R. C., 1
Colas-Linhart, N., 885
Collins, A. C., 171
Commissaris, R. L., 451
Connell, J. M., 469
Cooper, S. J., 51
Corrigall, W. A., 351
Costall, B., 607, 955
Cottrell, G. A., 307
Coughlan, J., 955
Crocker, A. D., 511
Culberson, J. W., 419
Czyrak, A., 557

Darling, N. K., 705
Davis-Street, J. E., 677
De Bellard, M. E., 133
DeBold, J. F., 357
de Caro, G., 823
de Castro, J. M., 923
de Luca, C., 933
Denton, D. A., 823
Desaubry, L., 85
Dickson, C. T., 847
Dilsaver, S. C., 523
Dodd, R. H., 281
Dohanich, G. P., 791
Dokla, C. P. J., 151
Domeney, A. M., 607, 955
Doty, R. L., 699
Dourish, C. T., 51
Dunlap, W. P., 791
Dwivedi, C., 767

Eisenberg, M. S., 865
Eison, A. S., 251
Ekman, R., 165
Ellison, G., 489
English, M. J. M., 157
Epstein, L. H., 671
Erwin, V. G., 469
Eterović, V. A., 255
Evans, E. B., 631
Evans, S. M., 971

Fahey, M. A., 949
Falk, J. L., 187, 419
Fanselow, M. S., 69
Fantino, M., 885
Fassos, F. F., 219

Feeney, D. M., 497
Feenstra, M., 903
Ferchmin, P. A., 255
Fernandez-Briera, A., 75
Fernández-Guasti, A., 263
Fernstrom, M. H., 671
Ferré, S., 481, 753
Ferrer, A. C., 127
Fico, T. A., 93
File, S. E., 317
Fischer, J. E., 195
Fitten, L. J., 553
Flemmer, D. D., 523
Foley-Nelson, T., 195
Fontana, D. J., 451
Forster, M. J., 747
Francès, H., 841
Frank, C., 999
Frank, R. A., 743
Franklin, K. B. J., 157
Freed, W. J., 693
Frenk, H., 1
Froehlich, J. C., 385
Fudala, P. J., 89
Fujiwara, H., 391

Gadek, M. A., 503
Gallo, M., 543
George, F. R., 245
Gerrard, P. A., 955
Gessa, G. L., 601
Giagnoni, G., 137
Giardino, L., 937
Gilmore, D. P., 571
Giorgi, O., 877
Glennon, R.A., 517
Glowa, J. R., 803
Gomá, M., 481
Granier, M., 127, 133
Grilly, D. M., 269
Grogan, T. W., 269
Groppetti, A., 137
Grupp, L. A., 493
Gudehithlu, K. P., 767
Guix, T., 481, 753
Güngör, M., 47, 829

Haertzen, C. A., 397
Hanna, J. A., 553
Haraguchi, M., 259
Hardwick, W. C., 797
Harper, A. E., 911
Harrell, L. E., 21
Harts, J., 385
Hatake, K., 437
Hellevuo, K., 721
Herberg, L. J., 815
Hishida, S., 437
Hoffman, A. J., 211
Hughes, R. A., 567
Hunt, T., 373
Hunter, R. E., 791
Huston, J. P., 989
Hutchings, D. E., 93

Ijiri, I., 437
Irby, D., 739
Itoh, T., 391
Iwai, A., 727
Iwamoto, E. T., 89

Jackson, D. M., 861
Jacob, R. G., 671
Jaffe, K., 127, 133
James, H., 617
Janal, M. N., 397
Jané, F., 481, 753
Jeans, M. E., 157
Jeffreys, R. D., 803
Jias, L. M., 489
Johanson, C. E., 971
Johnson, M. P., 211
Johnston, H. M., 571
Johnston, J. L., 677
Jones, B. C., 469

Kamei, J., 473
Kamien, J. B., 117, 949
Kanarek, R. B., 301, 665
Kao, L. C., 291
Kasuya, Y., 473
Kawai, T., 413
Keller, E., 335
Kellstein, D. E., 1
Kelly, M. E., 607, 955
Khidichian, F., 841
Klawans, H. L., 291
Kleven, M. S., 637
Knott, V. J., 341
Koob, G. F., 889
Korpi, E. R., 721
Koyuncuoğlu, H., 47, 829
Kragh, R., 237
Kumor, K. M., 397
Kunko, P. M., 871

Lac, S. T., 237
Lagarde, D., 713
Lal, H., 747
Landrum, R. E., 477
Landrum, T. A., 477
Lang, A., 855
Langan, M. C., 363, 379
Lau, C. E., 187, 419
Laurent, J., 713
Lemaire, G. A., 245, 443
Leong, F. W., 363, 379
Li, C., 699
Li, T.-K., 385
Lin, D. H., 291
Lin, W., 739
Lisciotto, C. A., 357
Ljungberg, T., 111
Llorens, J., 1003
Logan, L. G., 121
Louisot, P., 75
Lumeng, L., 385

McBurnie, M. I., 823
McDaniel, K. L., 429
McKearney, J. W., 181
McMillan, D. E., 797
McMillen, B. A., 465

Madras, B. K., 949
Maher, T. J., 865
Maj, J., 557
Malarkey, W., 767
Marczynski, T. J., 503
Margraf, R. R., 251
Marks-Kaufman, R., 301, 665
Marsland, A. L., 41
Martin, R. J., 225
Martin, W. R., 347, 651
Mason, S. E., 785
Massi, M., 823
Massi, P., 137
Massotti, M., 933
Masukawa, Y., 413
Mathis, C. A., 211
Mayer, D. J., 1
Mehrabani, P. A., 99
Meisch, R. A., 245, 443
Melchers, B. P. C., 321
Melchior, J.-C., 885
Mele, L., 933
Melis, M. R., 601
Meliska, C. J., 477
Menon, M. K., 553
Messiha, F. S., 29
Meyer, M. E., 307
Meyer, S., 775
Miczek, K. A., 357
Milhaud, C., 713
Milius, R. A., 949
Miñano, F. J., 465
Mintz, M., 815
Misenheimer, B., 517
Misslin, R., 85
Mitchell, J. B., 367, 643
Miyate, H., 143, 391
Mogilnicka, E., 557
Molina, V. A., 335
Monier, C., 841
Moody, C. A., 743
Morelis, R., 75
Mos, J., 781
Mucha, R. F., 219
Mueller, K., 871
Mundy, W. R., 429
Murai, S., 391
Murray, A. M., 105
Murúa, V. S., 335
Museo, E., 735
Myers, R. D., 465

Nagahama, H., 391
Naylor, R. J., 607, 955
Nelson, J. L., 195
Neumeyer, J. L., 949
Nichols, D. E., 211
Nierenberg, J., 405
Nilekani, S. P., 705

Odio, M., 963
Oeltgen, P. R., 705
Ogawa, M., 473
Oishi, R., 897
Okada, K., 897
Olivier, B., 781
Onaivi, E. S., 955
O'Neill, S. K., 833
Ouchi, H., 437
Owens, S. M., 797
Ozawa, Y., 727

Papadakis, E., 451
Parenti, M., 137
Parker, L. A., 583
Parker, S. C., 151
Parolaro, D., 137
Parsons, D. S., 21
Patrini, G., 137
Paule, M. G., 759
Pauly, J. R., 171
Payne, A. P., 571
Peagler, A., 21
Penetrante, M. L., 363, 379
Perkins, K. A., 671
Perlanski, E., 493
Perrignon, A., 861
Perryman, K. M., 553
Peters, D. A. V., 943
Peters, G., 61
Philippens, H. C. H. M., 561
Phillips, A. G., 685
Piazza, P. V., 937
Picker, Z., 327
Poling, A., 537
Poltorak, M., 693
Pomerantz, S. M., 659
Poulos, C. X., 373
Pournaghash, S., 803
Prat, G., 481, 753
Pruitt, T. A., 347
Puerto, A., 543
Pugsley, T. A., 589

Raffalli-Sebille, M.-J., 281
Rebec, G. V., 55
Repa, J. J., 911
Ribbi-Jaffe, A., 127
Rigaud, D., 885
Riley, A. L., 803
Risser, J. M., 699
Roane, D. S., 225
Robinson, N. L., 617
Roldán-Roldán, G., 263
Rose, I. C., 815
Rosenwasser, A. M., 35
Rozen, R., 885
Russell, R. W., 511
Rönnbäck, L., 15

Saeki, K., 897
Sağduyu, H., 47, 829
Sagratella, S., 999
Saha, J. K., 949
Saito, H., 231
Saito, Y., 391
Sakaki, N., 437
Saldívar, A., 263
Salmon, P., 41
Samson, H. H., 259
Satter, B. C., 767
Schanley, D. L., 363, 379
Schechter, M. D., 527
Schlinger, H., 537
Schreiber, J. F., 889
Schulze, G. E., 759
Schwarting, R. K. W., 989
Schwarz, R. D., 589
Scotti de Carolis, A., 999
Seale, T. W., 121
Seeland, K. J., 705
Seiden, L. S., 995
Sexton, J. E., 671
Sharma, H. M., 767
Shaw, C., 493
Shulgin, A. T., 211
Singer, G., 739
Singh, R., 291
Siwanowicz, J., 557
Slangen, J. L., 781
Sloan, J. W., 347, 651
Sobrian, S. K., 617
Soosaar, A., 855

Spealman, R. D., 949
Spencer, C. J., 589
Ståhle, L., 201
Stancampiano, R., 601
Stanford, S. C., 41
Starmer, G. A., 861
Starr, B. S., 285
Starr, M. S., 285
Steger, R. W., 577
Steiner, H., 989
Stewart, J., 367, 643
Stiller, R. L., 671
Stokes, D. L., 617
Stroet, J., 903
Suh, H. H., 807
Suñol, C., 1003
Suzuki, T., 413
Swiergiel, A. H., 61
Szmydynger-Chodobska, J., 823

Tablante, A., 127, 133
Tang, M., 187, 419
Taniguchi, T., 437
Tarjan, E., 823
Tasker, R. A. R., 157
Tejwani, G. A., 767
Terry, P., 41
Tews, J. K., 911
Thal, L. J., 151
Tilson, H. A., 429
Tolliver, G. A., 259
Tomkins, D. M., 607, 955
Toth, P., 493
Toubas, P. L., 121
Tseng, L. F., 807
Tuominen, K., 721
Turner, L. M., 617
Tusell, J. M., 1003
Tyers, M. B., 955

Ullman, E. A., 171
Ungerstedt, U., 201
Urbanicic, M., 503

Vanderwolf, C. H., 847
van Haaren, F., 903
Van Hartesveldt, C., 307
van Helden, H. P. M., 321
van Hest, A., 903
Vanwersch, R., 561
Vasar, E., 855
Vécsei, L., 165
Venault, P., 281
Vigorito, M., 187
Virus, R. M., 637
Vogel, E., 85
Volosin, M., 335

Waddington, J. L., 105
Wala, E. P., 347, 651
Walker, M. J. K., 219
Ward, L., 785
Weinger, M. B., 889
Weisinger, R. S., 823
Weiss, S. M., 775
Wellman, P. J., 457, 461
Wenger, G. R., 595, 631
Wermuth, C. G., 85
Wessinger, W. D., 797
Widerlöv, E., 165
Wilks, L. J., 317
Willard, M., 85
Wilson, C. A., 571
Wise, R. A., 735
Wolgin, D. L., 273
Wolthuis, O. L., 561
Woolverton, W. L., 117, 637
Wright, D. W., 595
Wright, R. N., 251

Yamamoto, M., 727
Yanaura, S., 413
Ybema, C. E., 781
Yocca, F. D., 251
Young, S. N., 157

Zabala, N. A., 127, 133
Zacny, J. P., 637, 971
Zhang, T. J., 291